The topics I was studying when I received the 1970 Minkowski Award were the the regulation of adipose tissue metabolism and the mechanism of insulin secretion. I had shown, as had several others, that adipose tissue was not as inert as it had been claimed to be for years but that it was very active metabolically and under the control of many hormones, insulin in particular. In collaboration with Doctor A. Lambert at the Institut de Biochimie clinique of Professor A. E. Renold we had also demonstrated, albeit indirectly, that insulin secretion was a cyclic AMP-dependent process [1] .
In 1971, I started a new research group, the "Laboratoires de Recherches Mrtaboliques", Faculty and Department of Medicine (Geneva) of which I had been nominated Professor and Head by the State of Geneva. I also moved to a new building , the "Fondation pour Recherches Mrdicales" Which made available to me, progressively, research space. It is within this buitding that Nestl6 S.A. (Vevey) constructed for our group an excellent animal quarter. Our gratefulness to this company for its scientific and financial support is immense, all the more that it has always respected our academic freedom, a remarkable trait indeed. In 1970, our group consisted of five persons; now the number is 20-24. The challenge over the years was to create an entirely new research group, at a time when the oil crisis, and the money problem derived~ from it, was starting. The acknowledgements at the end of the present article give an idea of the many institutions which supported us financially and complemented the official State budget which tends, as money gets scarce, to finance teaching and administration more than research.
My research was collaborative: it involved many persons to whom I am greatly indebted. The overall strategy chosen was to study the regulation of insulin target tissues in normal and obese rodents, in an attempt to understand a possible primary aetiology of obesity syndromes and their relationship to Type 2 diabetes.
We started by setting up (Dr.F.AssimacopoulosJeannet in collaboration with Dr. J. H. Exton, who was invited professor in Geneva) a technique to perfuse livers from normal mice. This was a novelty as all scientists were working, at that time, with perfused rat livers. Mouse liver weight is about 1.2 g while rat liver weight is 12 g, a substantial difference when it comes to perfusing the organ. As you can see from Figure 1 , perfused livers from normal mice responded well to glucagon, epinephrine and cAMP [2] . In these perfused mouse livers we investigated many aspects of the normal liver, in particular the role microtubules and microfilaments play in protein and lipoprotein secretion [3] [4] [5] [6] [7] [8] . Dr. Y. Le Marchand-Brustel played a key role in this work as she did, together with Dr. F. Assimacopoulos-Jeannet, Dr. E. G. Loten and others, in the initial studies of obesity syndromes. I shall not summarize our data pertaining to the normal regulation of insulin target tissues as I will concentrate on the pathophysiological aspects of our research effort.
We chose to perfuse the liver of the normal mouse because we wanted to investigate subsequently livers of genetically obese animals. At that time the animal model most easily available was the ob/ob mouse, and its metabolism had been little studied. We found that perfused livers of genetically obese (ob/ob) mice had the following abnormalities (Fig.2): (a) was greatly enhanced compared with controls; (b) they oversecreted triglycefides as VLDL; (c) the percentage of VLDL secreted was the same in livers of both lean and obese mice, thus providing an explanation as to why the hepatic parenchyma of obese animals was infiltrated with fat [9] . We also observed, as shown by Figure 3 , that the same abnormalities were seen in perfused livers from ventromedial hypothalamic (VMH)-lesioned animals [10, 11] . It also appeared that over-synthesis of lipids in ob/ob mice was not restricted to the liver but was present in adipose tissue as well (Fig.4) [12]. This also turned out to be true for adipose tissue obtained from mice rendered obese via hypothalamic lesions (Fig. 8 A) [13]. We thus began to think that a common pathology was somehow linking genetic and hypothalamic obesity syndromes. We were struck by the observation that both types of obese animals had high basal plasma insulin levels (e. g. genetically obese ob/ob mice: 5-25 ng/ml; hypothalamic obese mice: 7-15ng/ml, at the age of 8-15 weeks). We then hypothesized that livers and adi- , 00] We therefore came to the conclusion that hyperinsulinemia was probably a key factor in bringing about the obesity in the syndromes just mentioned. We started thinking that insulin oversecretion, as it was present both in genetic obesity (in which Central Nervous System (CNS) defects, albeit unrelated to the regulation of insulin, had been described) [15, 16] and in obesity provoked by lesions of the hypothalamic area, might find its origin within the CNS. We realized that hyperinsulinemia was a defect placing obese rodents in a series of vicious circles that prevented them ever regaining a nor- 
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G~G-B-PIFA.T_G q G~G-6-P.FA. TG [17, 18] . This indicated that oversecretion of insulin made hyperinsulinemia worse as it partly prevented normal degradation of the hormone. By 1976 there were debates about the cause, or at least about the cause-effect relationships, of the various defects observed in obesity syndromes. Some thought that hyperinsulinemia was important; others were proposing that it was not important -they often measured basal, and not substrate-induced insulin output. Others suggested that insulin resistance was a primary event that would produce (via increasing blood sugar) insulin oversecretion [19] . As summarized above we could not think that insulin resistance was an early event in our animal models, in view of the observed overstimulation of metabolic pathways. In an attempt to clarify the sequence of events occurring in obesity, we carried out longitudinal studies summarized in Figure 7 -10 [13] . We first used hypothalamic obesity (gold-thio-glucose, (GTG)-treated mice) to observe: (a) that down-regulation of insulin receptor numbers took time to occur, and was seen only when insulinemia was increasing to rather high basal values (Fig. 7) ; (b) that target tissues (taking the particular example of adipose tissue) were, in the initial phase of the syndrome, over-responsive to insulin (Fig. 8 a) and became insulin-resistant only at a later stage (Fig. 8 b) . This evolution was again observed in both genetic as well as in hypothalamic obesities [13, 20] . Such initial overstimulation and subsequent insulin resistance was later shown (in VMH-lesioned rats studied by euglycemic clamps) to prevail not only in liver and adipose tissue, but in the muscle mass as well [21] ; (c) we also observed that muscle insulin resistance was well correlated with the degree of hyperinsulinemia prevailing at the time of the experiment, i.e. at the time when the (soleus) muscle was removed and incubated. This is shown in Figure 9 and suggests that hyperinsulinemia could well be a driving force not only for the occurence of obesity but for that of insulin resistance [13] .
TG-VLDL
Of note is the fact that some pathways do not become insulin resistant. Thus, as illustrated by Figure10, VLDL output (as well as lipid synthesis, not shown) by perfused livers of hypothalamic obese mice always remains higher than normal. This observation holds true for most animal models of obesity as does the finding that adipose tissue lipoprotein lipase activity usually remains high in obese rodents [22] . Thus, despite the occurrence of insulin resistance, some pathways (usually involved in fat deposition) remain overactive, thereby maintaining the state of obesity. An explanation has recently been proposed for the lack of insulin resistance in liver lipogenesis: under basal conditions the hepatocytes of genetically obese (fa/fa) rats are characterized by increases in fructose 2,6-bisphosphate and glycerol 3-phosphate concentrations as well as in pyruvate kinase activity. This would suggest a continuous stimulation of glycolysis, with channeling of glucose-carbon into lipids [22, 23, 24] . In fact in appears from our recent work thatfedlean rats infused with insulin, as studied in vivo by a euglycemic clamp, may have similar stimulation of glycolysis and of lipogenesis as fed obese animals chronically exposed to their high basal insulinemia [22; 23, 25] .
Our results have shown that muscles of obese rodents become insulin-resistant, a resistance characterized by decreased insulin receptor number, decreased insulin sensitivity and decreased responsiveness of pathways of glucose metabolism [26] [27] [28] [29] . It is of interest to note that the severity of muscle insulin resistance increases with the duration of the syndrome, as summarized by Figure 11 . In this work muscles of normal and genetically obese (fa/fa) rats were studied using a technique of incubating strips of soleus muscles with their tendons. This method allows the preparation of four muscle strips from the same animal and avoids the problem of substrate diffusion [30] . Figure11 (upper panel) shows that, at the beginning of the obesity syndrome (when hyperinsulinemia is still relatively moderate), glycolysis in muscles from obese animals is less insulin-sensitive than controls, an abnormality that is the consequence of decreased insulin receptor numbers. Later on (Fig. 11, lower panel) the muscles of the obese rats become not only less insulin-sensitive but also less insulin-responsive (poor response to insulin even at supramaximal concentrations). The latter abnormality can be accounted for only by post-insulin binding alterations. It was subsequently shown [28] [29] [30] that those post-insulin binding defects of muscles from obese rodents include a decrease in glucose transport per se [29] and an increase in the utilization of endogenous lipids which, by increasing intracellular citrate concentrations, inhibits the glycolytic pathway at the phosphofructokinase level [30] . Increased endogenous fat utilization could be secondary to the lack of availability of energy from glucose-carbon. The latter defect could be due to an altered glucose transport system. We described several years ago and, as depicted by Figure 12 , that glucose transport was inhibited by cytochalasin B [31] . This field remained dormant until two independent groups [32, 33] , one of them using cytochalasin B as a marker of the glucose transport system [32] , demonstrated in adipose tissue, that insulin rapidly, specifically and reversibly produced a translocation of glucose transporters from an intracellular membrane pool to the plasma membrane. We have adapted this technique to other tissues, in particular to muscle [34, 35] . As illustrated in Figure l3 we have confirmed that in muscle (diaphragm) a similar system of translocation of glucose transporters prevails and that, when exposed to insulin, the number of glucose transporters at the plasma membrane increases while that of the microsomal pool decreases, the total number of glucose transporters remaining unchanged [34] . Work is now being carried out to attempt to determine whether and how the system of the glucose transport units is abnormal in muscles as well as in brown adipose tissue of obese rodents (D. Zaninetti and R. M. Greco, unpublished data).
The simplest way to summarize our views about the evolution of the obesity syndrome is to consider Figure  14 [36] . The studies summarized by this figure have been and still are being extended by the use of two techniques which we have set up for small rodents: (a) the eu-and hyperglycemic clamp techniques that enable us to study hepatic glucose production and overall glucose metabolism in vivo under steady-state conditions [37] ; and (b) the use of non-steady-state kinetics (double tracer technique) to measure hepatic glucose production and-overall glucose metabolism in conscious, freely moving rats, during the spontaneous ingestion of a glucose-meal [38] . For example, and as can be seen from Figure 15 , the euglycemic clamp technique enabled us for the first time to detect an in vivo defect in glucose production by the livers of genetically obese (fa/fa) rats in which the high basal or induced increases in plasma insulin levels are unable to shut off hepatic glucose production [37] . Full dose responses of insulin (using the euglycemic clamps) allowed us recently to demonstrate severe in vivo insulin resistance of peripheral glucose utilization (mostly muscle mass) in the fa/fa rats [39] .
Similarly, using the same technique, we have shown that the process of hepatic glucose production in the fa/fa obese rats can be shut off only when insulin is used at the pharmacological concentrations of about 20,000mU/1 [39] . Here again using the clamp techniques, analogous data have been observed in VMH-lesioned obese rodents [21] . The underlying mechanisms of this defect in hepatic glucose production are as yet unclear. For instance, it could be a combination of intrinsic hepatic abnormalities such as the inability of obese rodents to inhibit phosphorylase a due to its sustained activation via high cytosolic Ca ++ that would stimulate phosphorylase kinase [22, 40, 41] , as well as to the presence of catabolic hormones (glucagon, glucocorticoids) that would be insufficiently counteracted by insulin in vivo [21, 22, 39] . Recently it has been shown (using non-steady-state kinetics) that conscious, freelymoving, genetically obese (fa/fa) rats are unable, during the spontaneous ingestion of a glucose-meal, to inhibit hepatic glucose production and that this abnormality is the likely explanation for their abnormal oral glucose tolerance described below (F.Rohner-Jeanrenaud, J. Proietto and E. Ionescu, unpublished data.).
As mentioned above, we place great emphasis upon oversecretion of insulin as we think that in both VMHlesioned and genetically obese (fa/fa) rats, it may be one of the main aetiological factors that appears to relate to a series of CNS disorders. When surveying the literature and our own data, it is rather evident that hypersecretion of insulin is responsible for initially inducing obesity and that, provided hyperinsulinemia is present, hyperphagia is not necessary but acts only as an amplification factor [19, 22] . We were of course aware of the many data showing that lesions of the hypothalamus resuked in high plasma insulin levels [19, 22] . The question we posed was how rapidly the increased insulin output would occur after VMH lesions. The data are summarized in Figure16. One can see that, within 10 min following lesions of the VMH area of normal anaesthetized rats, substrate (glucose)-induced insulin output is increased [42, 43] . This change is mediated via the vagus nerve as it can be completely and rapidly reversed by a superimposed vagotomy [43] . Thus, as described in details elsewhere [44] , we propose that acute VMH lesions produce rapid disturbances of the CNS homeostasis that result, via unknown mechanisms, in a stimulation of the motor neurons of the vagus in the brain stem, producing increased efferent parasympathetic activity. These motor neurons linked to the endocrine pancreas have been shown to lie within the mid part of the dorsal motor nucleus of the vagus nerve (DMX) and in the nucleus ambiguus (NA) [45] [46] [47] . The alteration of efferent parasympathetic pathways following VMH lesions is all the more striking since, in normal rats, the efferent vagus that reaches the pancreas is under a powerful tonic GABA inhibitory action, probably to prevent hypoglycemia [48] . The parasympathetic origin of the disturbance produced by VMH lesions is further substantiated by the observation that not only insulin but also glucagon secretion is augmented following VMH lesions, an atropine-inhibitible defect (Fig.17 ) [49] [50] [51] . The increased insulin output following VMH lesions occurs rapidly enough to make it a likely candidate as the cause of subsequent stimulation of lipogenic pathways. Furthermore the accompanying increase in glucagon output is one of the reason why, even prior to the development of insulin resistance, VMH-lesioned rats are never hypoglycaemic.
Thus obesity may be viewed as a neuroendocrine disorder. This concept has been strengthened by recent data bearing on the study not of parasympathetic but of the sympathetic outflow. In this work, normal rats were anaesthetized and placed on a stereotaxic frame. The spontaneous activity of a purely sympathetic nerve was studied by electrophysiological means and, for convenience, the sympathetic nerve reaching the interscapular brown fat was selected. The nerve was cut and the electrode placed on the proximal end of the cut nerve, thereby enabling a recording of only efferent nerve activity [52] . As can be seen by Figure 18 , electrolytic lesions of the VMH area resulted in a marked and rapid (within 30m in) decrease in the efferent sympathetic outflow. This certainly has influence on the occurrence and maintenance of obesity by preventing heat dissipation mechanism(s). Indeed it was shown, in collaboration with the Department of Physiology of Geneva, that brown adipose tissue of both genetically and VMHlesioned obese rodents lost their ability to oxidize fat in response to the electrical stimulation of their sympathetic nerves or to other stimuli [53] [54] [55] [56] . Decreased sympathetic outflow could also play a role (if it were also to exist at the level of the endocrine pancreas) in reinforcing hyperinsulinemia as it would remove the usual inhibitory effect of the sympathetic system on the B cell.
The potential physiopathological relevance of studying VMH-lesioned rats would be little if the changes observed were restricted to a syndrome that is artificially produced. This is however not the case; similar changes appear to occur in the genetically obese OCa/ fa) rats. Small pups that will grow subsequently to become normal or obese rats have been studied recently with regard to the secretory activity of their endocrine pancreas. Unweaned (17-day-old) pups have been thus investigated prior to the occurrence of obesity, at a time when they are indistinguishable from each other, have the same body weight and normal basal insulinemia. After testing with an IV challenge with glucose or arginine all pups are placed back with their mother, subsequently weaned and kept until some of them (25%, as we deal with a recessive gene) become obese. The obese rats are retrospectively referred to as pre-obese [57, 58] . Figure 19 shows that genetically pre-obese pups do oversecrete insulin in response to glucose (or arginine) compared to the pups that remain lean. Moreover, the insulin oversecretion of the pre-obese animals is, when arginine is used as substrate, accompanied by glucagon oversecretion. This double hormonal secretory defect is mediated by the efferent vagus as it can be inhibited by acute atropine adiminstration [57, 58] . Thus one can hypothetize that, in the genetically pre-obese OCa/fa), a pathological situation analogous to that produced by acute VMH lesions prevails. Firstly insulin oversecretion is an early abnormality, that can therefore be causal in the aetiology of obesity. Secondly insulin and glucagon hypersecretion is an abnormality that is related to CNS-borne increase in the efferent vagus tone reaching the pancreas. One should stress that other investigators have found that noradrenaline turnover, at the level of the pancreas and of brown adipose tissue, is decreased in genetically obese rats [22] . Moreover the ability to dissipate energy as heat (a sympathetic nerve mediated process in normal animals) is decreased early in the evolution of the syndrome, i.e. in genetically pre-obese pups [22] .
These data are in keeping with the view that, in genetically obese rodents, increased parasympathetic efferent activity is accompanied by decreased sympathetic activity. This view is schematized in Figure 20 and is justified in more detail elsewhere [22, 44] . We consider that at least some types of spontaneous obesities could be the result of a neuro-endocrine pathology with the metabolic consequences indicated in the figure. If such a mechanism underlies some types of human obesity, it should explain why treatment is usually unsuccessful since it is, most of the time, symptomatic in its nature. As long as CNS disorders (with their metabolic consequences) are not therapeutically altered, body weight is bound to return to a "higher set point" [59, 60] . As can be seen from Figure 20 , there are many neural afferences originating from the periphery to reach the brain, CNS integration of these afferent informations with resulting neural efferences that influence peripheral organs [44, [61] [62] [63] [64] . Several of these processes could be altered in obesity syndromes and we attempt studying them at the moment. We have shown for example that, when an oral glucose tolerance test is performed in conscious, freely moving genetically obese (fa/fa) rats, such tolerance is abnormal while it is not when the same glucose load is given intravenously [65] . This could be due in part to abnormal neural afferent input (from the oropharynx or the gut) with defective or non-operative cephalic phase insulin output or other defective reflex mechanisms [66] . These defects could result in inappropriate timing and/or dynamics of meal-induced insulin output that, from the data of others [67] , appears to have a strong influence on normal disposal of glucose. This or other defects in the integration of afferent information within the CNS would also result in the inability of ingested glucose and released insulin to shut off hepatic glucose production and/or to clear ingested glucose adequately, as has been recently suggested by this laboratory (J. Proietto, E. Ionescu and F. Rohner-Jeanrenaud, unpublished data). Figure 20 also mentions the presence of several peptides. Some of them increase plasma glucose levels; others stimulate insulin secretion [22] . The physio-and pathological roles of these peptides are as yet unknown. We have made great efforts to study a hypothalamic peptide that possesses in vivo and in vitro insulin secretion promoting activity, as illustrated by Figure 21 and 22 [68, 69] . Thus ( Fig. 21) partially purified hypothalamic extracts (G-50 Sephadex chromatography) from normal rats produce, when injected in vivo to normal anaesthetized recipient rats, rapid and transient rises in plasma insulin levels. The factor(s) responsible for this effect is of small molecular weight. Catecholamines, acetylcholine and enkephalins can be excluded as causes of the effect observed. The finding that exposure of those partially purified extracts from ventrolateral hypothalamus (VLH) to trypsin or collagenase markedly decrease their in vivo insulin secretion promoting activity suggest that this active component(s) is of polypepfidic nature and is also thermostable [68] . Furthermore, as can be seen in Figure 22 , when the active fractions of the partially purified hypothalamic extract (cf. Fig.21 ) are pooled and infused into normal perfused pancreases, a pronounced stimulatory effect on insulin secretion is observed at a low glucose concentration in the medium, indicating that the peptidic factor(s) is not an incretin [69] . This small peptide (about 1000 Daltons) appears to be present both in the hypothalamus and the plasma of normal rats and is currently being purified by HPLC; its amino-acid analysis is close to completion (E. Bobbioni, W. Schlegel and D.Ashley, unpublished data). It is hoped that we shall soon be able to deter-mine its amino acid sequence. Once the peptide is fully characterized, we shall raise an antibody against to set up a radio-immunoassay. This will allow us to determine its physiology and pathology: it is conceivable that such a study may re-inforce our overall concept (shown by Fig.20) that obesity, possibly insulin resistance and the evolution toward Type 2 diabetes may both have a neurological basis.
